Anti-Human CD8 (Clone SK1) – Purified No Carrier Protein

Recombinant protein of human CD8

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.

Liquid

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

FC,
IHC,

SK1 activity is directed against human CD8a.

CD8 is an integral membrane protein essential to immune response that acts as a co-receptor for the MHC class I molecule: peptide complex¹. CD8 recruits the Src kinase LCK to the vicinity of the TCR-CD3 complex, leading to activation of cytotoxic T-lymphocytes which recognize and eliminate infected cells and tumor cells. CD8⁺ T cell differentiation is tightly regulated, and the T cell response depends on the antigen encounter. Immune response to acute infection,autoimmunity, graft vs host disease, tumors, chronic infection, and self-tolerance are all affected by CD8⁺ T cells².

When expressed on thymus-derived T cells, CD8 molecules are seen as CD8α/CD8β heterodimers, while they are CD8α homodimers when expressed on intraepithelial lymphocytes from the gut, CD8⁺ dendritic cells³, or a subset of human natural killer cells⁴. Gene expression is closely regulated with CD4, with expression of CD4 and CD8 used to distinguish the four major stages of T cell development⁴.

SK1 blocks MHC-peptide tetramer binding to the TCR, and the effect is not due to steric hindrance^5,6. SK1 is commonly used as a marker in flow cytometry experiments^5,7-12.

CD8 is present on thymocytes, T lymphocytes, and natural killer cells.

MHC Class I molecules

P01732

1 https://www.uniprot.org/uniprotkb/P01731/entry
2 Philip M, Schietinger A. Nat Rev Immunol. 22(4):209-223. 2022.
3 Kioussis D, Ellmeier W. Nat Rev Immunol. 2(12):909-919. 2002.
4 Ellmeier W, Haust L, Tschismarov R. Cell Mol Life Sci. 70(23):4537-4553. 2013.
5 Campanelli R, Palermo B, Garbelli S, et al. Int Immunol. 14(1):39-44. 2002.
6 Geng J, Altman JD, Krishnakumar S, et al. Elife. 7:e36341. 2018.
7 Santos RLA, Bai L, Singh PK, et al. Nat Commun. 8(1):1692. 2017.
8 Nguyen LT, Saibil SD, Sotov V, et al. Cancer Immunol Immunother. 68(5):773-785. 2019.
9 Mann ER, Menon M, Knight SB, et al. Sci Immunol. 5(51):eabd6197. 2020.
10 Jilg N, Garcia-Broncano P, Peluso M, et al. J Infect Dis. 222(11):1837-1842. 2020.
11 Oberg HH, Janitschke L, Sulaj V, et al. J Leukoc Biol. 107(6):1081-1095. 2020.
12 Yamaguchi A, Kawagoe I, Inoue S, et al. J Thorac Dis. 13(9):5430-5438. 2021.